TLR9 and Huntington disease: This immunosuppressive effect of m/lEVs was observed either in B cells from HD or in patients with RA activated through BCR alone (signal 1), or with a TLR-9 agonist (CpG) that decreases the threshold of B cell activation [44] (signals 1 and 2).